Progression-free survival as a treatment gauge in pancreatic cancer

Tsuyoshi Shirakawa, MD, PhD, Eikoh Hospital and the Clinical Hematology Oncology Treatment Study Group, Fukuoka, Japan, discusses how progression-free survival (PFS) can be considered a surrogate marker for overall survival (OS), providing insights into treatment efficacy in pancreatic cancer. For patients requiring second-line therapy, nanoliposomal irinotecan is recommended as a first-line treatment option in the clinic, before choosing other therapeutic methods. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.